ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Shares Up 2.4% – Should You Buy?

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) traded up 2.4% during trading on Thursday . The stock traded as high as $65.01 and last traded at $64.90. Approximately 49,921 shares were traded during trading, an increase of 40% from the average session volume of 35,636 shares. The stock had previously closed at $63.35.

ALPS Medical Breakthroughs ETF Price Performance

The stock has a 50-day moving average of $55.25 and a two-hundred day moving average of $52.91.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Silver Oak Securities Incorporated purchased a new stake in shares of ALPS Medical Breakthroughs ETF in the 4th quarter valued at approximately $677,000. Delta Investment Management LLC purchased a new position in ALPS Medical Breakthroughs ETF during the 4th quarter worth approximately $6,112,000. Elevation Point Wealth Partners LLC purchased a new position in ALPS Medical Breakthroughs ETF during the 4th quarter worth approximately $459,000. Jane Street Group LLC acquired a new stake in ALPS Medical Breakthroughs ETF during the 4th quarter valued at $257,000. Finally, Janney Montgomery Scott LLC acquired a new stake in ALPS Medical Breakthroughs ETF during the 4th quarter valued at $220,000.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.